RU2005119995A - Препараты, содержащие антитела человека, применяемые в лечении микобактериальных инфекций - Google Patents
Препараты, содержащие антитела человека, применяемые в лечении микобактериальных инфекций Download PDFInfo
- Publication number
- RU2005119995A RU2005119995A RU2005119995/15A RU2005119995A RU2005119995A RU 2005119995 A RU2005119995 A RU 2005119995A RU 2005119995/15 A RU2005119995/15 A RU 2005119995/15A RU 2005119995 A RU2005119995 A RU 2005119995A RU 2005119995 A RU2005119995 A RU 2005119995A
- Authority
- RU
- Russia
- Prior art keywords
- antimycobacterial
- preparation according
- drugs
- treatment
- containing human
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 4
- 229940079593 drug Drugs 0.000 title claims 4
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000001355 anti-mycobacterial effect Effects 0.000 claims 9
- 239000003926 antimycobacterial agent Substances 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 102000010445 Lactoferrin Human genes 0.000 claims 2
- 108010063045 Lactoferrin Proteins 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 2
- 229940078795 lactoferrin Drugs 0.000 claims 2
- 235000021242 lactoferrin Nutrition 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Claims (10)
1. Антимикобактериальный препарат, содержащий человеческие поликлональные антитела класса IgG или секреторные IgG или их смеси, активный в отношении микобактериальных компонентов, а также подходящую фармацевтическую среду.
2. Антимикобактериальный препарат по п.1, который может необязательно содержать лактоферрин.
3. Антимикобактериальный препарат по п.1, содержащий человеческие поликлональные антитела в концентрации, варьирующей между 40 и 160 мг/мл.
4. Антимикобактериальный препарат по п.2, содержащий лактоферрин в концентрации, варьирующей между 10 и 20 мг/мл.
5. Антимикобактериальный препарат по п.1, содержащий смесь обоих антител в соотношениях варьирующих от 50:50 до 80:20.
6. Антимикобактериальный препарат по п.1, содержащий также усилители иммунитета и/или иммуномодуляторы.
7. Антимикобактериальный препарат по п.6, содержащий также усилители иммунитета и/или иммуномодуляторы, которые могут быть выбраны из природных, рекомбинированных, синтетической или генной группы.
8. Антимикобактериальный препарат по п.1, содержащий любую комбинацию инактивированных или аттенуированных штаммов, включая те, что демонстрируют гетерологичные антигены и/или антигены или кодирующие гены, соответствующие указанным антигенам.
9. Применение препаратов в соответствии с пп.1-8 для профилактики и лечения любого заболевания, обусловленного микобактериями.
10. Применение препаратов в соответствии с пп.1-8 в комбинации с антимикобактериальными лекарственными препаратами.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2002-0275 | 2002-11-25 | ||
| CU20020275A CU23406A1 (es) | 2002-11-25 | 2002-11-25 | Composiciones contienendo anticuerpos humanos para el tratamiento y profiláxis de infecciones por micobacterias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005119995A true RU2005119995A (ru) | 2006-03-20 |
| RU2350352C2 RU2350352C2 (ru) | 2009-03-27 |
Family
ID=32331941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005119995/15A RU2350352C2 (ru) | 2002-11-25 | 2003-11-25 | Препараты, содержащие антитела человека, применяемые в лечении микобактериальных инфекций |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060222642A1 (ru) |
| EP (1) | EP1582218B1 (ru) |
| CN (1) | CN100579581C (ru) |
| AR (1) | AR042140A1 (ru) |
| AU (1) | AU2003285261A1 (ru) |
| BR (1) | BR0316558A (ru) |
| CA (1) | CA2507338A1 (ru) |
| CU (1) | CU23406A1 (ru) |
| DE (1) | DE60324466D1 (ru) |
| MX (1) | MXPA05005669A (ru) |
| MY (1) | MY143402A (ru) |
| RU (1) | RU2350352C2 (ru) |
| WO (1) | WO2004047865A1 (ru) |
| ZA (1) | ZA200504773B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1664119A1 (en) | 2003-09-08 | 2006-06-07 | Medical Research Council | Method for the treatment or prophylaxis of tuberculosis |
| EP2821415B1 (en) | 2012-02-29 | 2021-03-31 | Otsuka Pharmaceutical Co., Ltd. | Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816563A (en) * | 1983-11-25 | 1989-03-28 | Amtron, Inc. | Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof |
| US5258177A (en) * | 1991-12-10 | 1993-11-02 | Alpha Therapeutic Corporation | IgA preparation and process of making the same |
| US20010007660A1 (en) * | 1997-06-04 | 2001-07-12 | Aharona Glatman-Freedman | Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis |
| AU8063798A (en) * | 1997-06-19 | 1999-01-04 | Regents Of The University Of California, The | Secretory immunoglobulin produced by single cells and methods for making and using same |
-
2002
- 2002-11-25 CU CU20020275A patent/CU23406A1/es unknown
-
2003
- 2003-11-24 MY MYPI20034528A patent/MY143402A/en unknown
- 2003-11-25 AU AU2003285261A patent/AU2003285261A1/en not_active Abandoned
- 2003-11-25 AR ARP030104344A patent/AR042140A1/es unknown
- 2003-11-25 MX MXPA05005669A patent/MXPA05005669A/es active IP Right Grant
- 2003-11-25 US US10/536,298 patent/US20060222642A1/en not_active Abandoned
- 2003-11-25 DE DE60324466T patent/DE60324466D1/de not_active Expired - Lifetime
- 2003-11-25 BR BR0316558-2A patent/BR0316558A/pt not_active IP Right Cessation
- 2003-11-25 EP EP03778232A patent/EP1582218B1/en not_active Expired - Lifetime
- 2003-11-25 WO PCT/CU2003/000015 patent/WO2004047865A1/es not_active Ceased
- 2003-11-25 CA CA002507338A patent/CA2507338A1/en not_active Abandoned
- 2003-11-25 CN CN200380109162A patent/CN100579581C/zh not_active Expired - Fee Related
- 2003-11-25 RU RU2005119995/15A patent/RU2350352C2/ru not_active IP Right Cessation
-
2005
- 2005-06-10 ZA ZA200504773A patent/ZA200504773B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY143402A (en) | 2011-05-13 |
| ZA200504773B (en) | 2007-12-27 |
| EP1582218A1 (en) | 2005-10-05 |
| AU2003285261A1 (en) | 2004-06-18 |
| BR0316558A (pt) | 2005-10-04 |
| MXPA05005669A (es) | 2006-02-22 |
| US20060222642A1 (en) | 2006-10-05 |
| CN1756565A (zh) | 2006-04-05 |
| CN100579581C (zh) | 2010-01-13 |
| WO2004047865A1 (es) | 2004-06-10 |
| CA2507338A1 (en) | 2004-06-10 |
| EP1582218B1 (en) | 2008-10-29 |
| CU23406A1 (es) | 2009-08-04 |
| DE60324466D1 (de) | 2008-12-11 |
| RU2350352C2 (ru) | 2009-03-27 |
| AR042140A1 (es) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2434638C2 (ru) | Вакцина альфа токсоида с.perfringens | |
| WO2005000244A3 (en) | Methods and compositions for treating rheumatoid arthritis | |
| EP0634937A1 (en) | Vaccines that contain non-ionic surfactant vesicles. | |
| EP2481422A3 (en) | Multiplex vaccines | |
| DK1549338T3 (da) | Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier | |
| FR2814958B1 (fr) | Composition vaccinale | |
| BR0313154A (pt) | Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b | |
| Schager et al. | IgG responses to porins and lipopolysaccharide within an outer membrane-based vaccine against nontyphoidal Salmonella develop at discordant rates | |
| Lee et al. | Unforeseen pathologies caused by malaria | |
| Kozel et al. | Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody | |
| EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
| Favoino et al. | Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice | |
| Chen et al. | Design of bacterial inclusion bodies as antigen carrier systems | |
| RU2005119995A (ru) | Препараты, содержащие антитела человека, применяемые в лечении микобактериальных инфекций | |
| Hoepelman | Current therapeutic approaches to cryptosporidiosis in immunocompromised patients | |
| DE60109922D1 (de) | Therapeutische verbindungen gegen eierstockkrebs | |
| Martínez-Gómez et al. | Protection against Toxoplasma gondii brain cyst formation in mice immunized with Toxoplasma gondii cytoskeleton proteins and Lactobacillus casei as adjuvant | |
| Cnops et al. | Maintenance of B cells during chronic murine Trypanosoma brucei gambiense infection | |
| Gupta et al. | Periodontal vaccine: A new vista in periodontology-A review | |
| Lee et al. | Monoclonal antibodies against Vibrio vulnificus RtxA1 elicit protective immunity through distinct mechanisms | |
| Chung et al. | Albert Léon Charles Calmette (1863-1933) and the antituberculous BCG vaccination | |
| Weibel et al. | Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines | |
| Piergili-Fioretti et al. | Re-evaluation of patients involved in a trichinellosis outbreak caused by Trichinella britovi 15 years after infection | |
| PANCORBO et al. | Digoxin pharmacokinetics in continuous peritoneal dialysis | |
| Brezis et al. | Nightmares from digoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20111126 |